Category Business

Neurocrine Biosciences Reports Q2 2024 Financial Results and Increases 2024 INGREZZA Sales Forecast

Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, expressed enthusiasm about the company’s growth prospects.…

Read MoreNeurocrine Biosciences Reports Q2 2024 Financial Results and Increases 2024 INGREZZA Sales Forecast

WuXi AppTec Reports Stable Operations and Growth in Q2 2024: Revenue Up 16% QoQ, Adjusted Net Profit Up 28.5% QoQ

WuXi AppTec Reports First Half 2024 Financial Results WuXi AppTec, a global leader in R&D and manufacturing services for the pharmaceutical and life sciences sectors, has announced its financial results for the first half of 2024, ending June 30. Key…

Read MoreWuXi AppTec Reports Stable Operations and Growth in Q2 2024: Revenue Up 16% QoQ, Adjusted Net Profit Up 28.5% QoQ

Autobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments

Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners and included new investors Canaan Partners, Monograph Capital, and…

Read MoreAutobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments

Gilead and Elton John AIDS Foundation Extend RADIAN Partnership to Tackle HIV in Eastern Europe and Central Asia

Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a five-year extension of the RADIAN® partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). This partnership aims to support vulnerable…

Read MoreGilead and Elton John AIDS Foundation Extend RADIAN Partnership to Tackle HIV in Eastern Europe and Central Asia

Opdivo® Approved in South Korea for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino) announced today that its Korean subsidiary, Ono Pharma Korea Co., Ltd. (OPKR), received additional approval from South Korea’s Ministry of Food and Drug Safety (MFDS) on July 17. The approval…

Read MoreOpdivo® Approved in South Korea for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma